IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer
Fang, Hong; Lin, Rong-Yan; Sun, Ming-Xia; Wang, Qian; Zhao, Yu-Liang; Yu, Jing-Lin; Tian, Yan; Wang, Xiao-Yun
关键词NSCLC gefitinib cisplatin gemcitabine adenocarcinoma survival associated influencing factors
刊名ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
2014
DOI10.7314/APJCP.2014.15.24.10967
15期:24页:10967-10970
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]PHASE-III ; CHEMOTHERAPY
英文摘要

Objective: To analyze the efficacy and survival associated factors of gefitinib combined with cisplatin and gemcitabine for advanced non-small cell lung cancer. Materials and Methods: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. Efficacy, survival time and adverse reactions were observed. The Kaplan-Meier method was adopted for analysis of survival and Cox regression for associated influencing factors. Results: The patients were followed up until October 31, 2013, and the median follow-up time was 19 months. Of 57 patients, there were 4 (7.0%) with complete remission (CR), 8 (14.0%) with partial remission, 31 (54.4%) with stable disease, and 14 (24.6%) with disease progression. The remission rate was 21.1% and the disease control rate was 75.4%. The median progression-free survival (PFS) time and the median overall survival time were 10 months and 15.2 months. The one-year, two-year and three-year survival rates were 47.4%, 23.3% and 10.0%. Gender and pathological types were the independent risk factors influencing PFS time (P=0.028, P=0.009). Tumor pathological type and early efficacy were independent factors for the prognosis (P=0.018, P=0.000). Adverse reactions were mostly rashes of I similar to II degree and diarrhea and slightly increasing level of aminopherase. The skin adverse event incidence of. degree or above was 1.8% (1/57) and brain metastasis was foudn in 31.6% (18/57). Conclusions: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb similar to IV NSCLC who received multiple cycles of chemotherapy.

语种英语
WOS记录号WOS:000351058900072
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65811
专题北京大学第一临床医学院
北京大学第一临床医学院_肿瘤化疗科
作者单位Peking Univ, Dept Oncol Chemotherapy, Hosp 1, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Fang, Hong,Lin, Rong-Yan,Sun, Ming-Xia,et al. Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer[J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION,2014,15(24):10967-10970.
APA Fang, Hong.,Lin, Rong-Yan.,Sun, Ming-Xia.,Wang, Qian.,Zhao, Yu-Liang.,...&Wang, Xiao-Yun.(2014).Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer.ASIAN PACIFIC JOURNAL OF CANCER PREVENTION,15(24),10967-10970.
MLA Fang, Hong,et al."Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer".ASIAN PACIFIC JOURNAL OF CANCER PREVENTION 15.24(2014):10967-10970.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Fang, Hong]的文章
[Lin, Rong-Yan]的文章
[Sun, Ming-Xia]的文章
百度学术
百度学术中相似的文章
[Fang, Hong]的文章
[Lin, Rong-Yan]的文章
[Sun, Ming-Xia]的文章
必应学术
必应学术中相似的文章
[Fang, Hong]的文章
[Lin, Rong-Yan]的文章
[Sun, Ming-Xia]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。